Adamas Pharmaceuticals Inc. (ADMS) has completed recruitment of its confirmatory phase III trial of ADS-5102 for the treatment of levodopa-induced dyskinesia, a motor complication associated with the treatment of Parkinson's disease.
The trial, dubbed EASE LID, which is enrolling approximately 120 individuals, is a 26-week multi-center, randomized, double-blind, placebo-controlled study assessing the efficacy of a 340 mg dose of ADS-5102 administered once daily at bedtime.
The company expects top-line results from the EASE LID trial to be available in the first quarter of 2016.
ADMS touched a new high of $27.98 on Thursday before closing the day's trading at $26.58, up 0.23%.
Shares of Aquinox Pharmaceuticals Inc (AQXP) plunged more than 67% on Thursday as the company's phase II trial with AQX-1125 in patients with chronic obstructive pulmonary disease, known as the FLAGSHIP trial, failed to demonstrate efficacy.
According to the trial results, patients treated with 200 mg oral, once daily AQX-1125 for 12 weeks showed no difference in COPD symptoms compared to placebo, as measured by EXACT, a patient-reported outcome tool. On the secondary endpoint of medically treated exacerbations there was also no benefit observed with AQX-1125.
In another phase II trial with AQX-1125 in patients with bladder pain syndrome/interstitial cystitis (BPS/IC), known as the LEADERSHIP study, the results of which were announced last month, although AQX-1125 demonstrated a reduction in pain for patients on AQX-1125 compared to those patients on placebo, the difference did not reach statistical significance.
AQXP cratered 67.48% on Thursday to close at $2.13.
Bacterin International Holdings Inc. (BONE.OB) expects total revenue for the second quarter of 2015 to be in the range of $10.0 million to $10.2 million, representing an increase of 12-15% when compared to $8.8 million reported in the year-ago quarter.
The company's revenue in the first quarter of 2015 was $9.5 million.
Bacterin is scheduled to report Q2, 2015 results in the second week of August.
BONE.OB closed Thursday's trading 5.17% higher at $3.05.
Dynavax Technologies Corp. (DVAX) has been asked by an Independent Data and Safety Monitoring Board to continue the ongoing phase III clinical study of HEPLISAV-B unchanged. HEPLISAV-B is the company's investigational hepatitis B vaccine for adults. This is the third review by the Data and Safety Monitoring Board.
Over 2,200 subjects have completed their final study visit and all study visits for HBV-23 are expected to be completed by October 2015. Top line results are expected to be released by early 2016.
To access our complete report on DVAX visit Emerging Biostocks.
DVAX closed Thursday's trading at $26.44, up 8.27%.
Epizyme Inc. (EPZM) has dosed the first patient in a phase II trial of its lead clinical candidate, Tazemetostat (EPZ-6438) in patients with relapsed or refractory non-Hodgkin lymphoma.
The trial is designed as a five-arm study, and will enroll up to 150 patients.
A second planned phase II trial of Tazemetostat in adult patients with INI1-deficient solid tumors is expected to initiate later in 2015. A phase I study in pediatric patients with INI1-deficient solid tumors is also expected to start later in 2015.
EPZM closed Thursday's trading at $22.97, up 0.83%.
IGI Laboratories Inc. (IG) has launched its seventh product, diclofenac sodium 1.5% topical solution, after receipt of the final approval from the FDA for an abbreviated new drug application.
The company now markets seven products in twelve presentations in an IGI label.
IGI Labs now has twenty-seven submissions, exclusive of its four partnered submissions, pending approval by the FDA, with a combined addressable market of over $939 million based on May 2015 data from IMS Health, and another fifteen more submissions planned before the end of this year.
IG closed Thursday's trading at $6.48, up 2.53%.
Shares of Ultragenyx Pharmaceutical Inc. (RARE) touched a new high on Thursday, following positive interim data from the first 12 patients in the ongoing pediatric phase II study of its recombinant human monoclonal antibody KRN23 against fibroblast growth factor 23 (FGF23) for the treatment of X-linked hypophosphatemia (XLH).
According to the study results, there was an improvement in mean rickets score after 40 weeks of treatment with investigational KRN23 in these patients.
The phase II study is being conducted under a collaboration and license agreement with Kyowa Hakko Kirin to develop and commercialize KRN23.
An additional 40-week analysis for 36 patients is planned for the fourth quarter of 2015.
RARE closed Thursday's trading 13.76% higher at 112.65 after touching an all-time high of $113.42.
Urologix Inc. (ULGX.OB) has decided to terminate and suspend the registration of its stock with the Securities and Exchange Commission on or about July 10, 2015. The company's common stock will cease trading on the OTCQB and commence trading on the OTC Pink marketplace.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.